Standard Review for Onyx’s Multiple Myeloma Drug Leaves Accelerated Approval In Question

Drug Industry Daily
A A
Onyx Pharmaceuticals’ multiple myeloma drug carfilzomib will receive a standard, 10-month, FDA review, another hurdle for the compound, which was expected to receive priority review.

To View This Article:

Login

Subscribe To Drug Industry Daily